Nkarta, Inc.
NASDAQ:NKTX · NASDAQ Global Select
+$0.10 today
Vol 0.34M · Avg 0.76M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-33.3%
avg -13.6%
ROIC
-31.2%
avg -28.3%
ROA
-25.8%
avg -25.9%
Analysis
ROA is currently the strongest return metric at -25.8% versus its period average of -25.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Paul J. Hastings | Chief Executive Officer & Director | $1.03M | — | 66 | $390,023.00 | 0.55% |
Nadir Mahmood | President and Principal Accounting & Financial Officer | $806,361.00 | — | 46 | $167,727.00 | 0.23% |
Shawn Rose | Chief Medical Officer and Head of Research & Development | $515,473.00 | — | — | $139,000.00 | 0.19% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
3
$68,812.75
Net Sentiment
$68,812.75
Net selling
Most Active
HASTINGS PAUL J
2 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Jan 15, 2026 | HASTINGS PAUL J Direct | Sell | 26.0K | $2.07 | $53,915.22 | |
| Jan 15, 2026 | Mahmood Nadir Direct | Sell | 5.6K | $2.07 | $11,693.43 | |
| Jun 18, 2025 | HASTINGS PAUL J Direct | Sell | 1.8K | $1.79 | $3,204.10 |
Analysis
Insiders reported 0 buys worth $0.00 and 3 sells worth $68,812.75 over the last 12 months. That adds up to net selling of $68,812.75. HASTINGS PAUL J was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Cybin Inc.
CYBN
$413.02M
Elicio Therapeutics, Inc.
NASDAQ:ELTX
$283.43M
Forte Biosciences, Inc.
NASDAQ:FBRX
$243.83M
Fate Therapeutics, Inc.
NASDAQ:FATE
$240.11M
Alector, Inc.
NASDAQ:ALEC
$169.87M
Molecular Partners AG
NASDAQ:MOLN
$154.17M
PepGen Inc.
NASDAQ:PEPG
$101.68M
Vor Biopharma Inc.
NASDAQ:VOR
$98.42M
Cassava Sciences, Inc.
SAVA
$63.77M
Applied Therapeutics, Inc.
APLT
$14.86M
Who manages NKTX?
Nkarta, Inc. (NKTX) lists 3 active executives. The top listed executive is Shawn Rose, Chief Medical Officer and Head of Research & Development.
Are NKTX insiders buying or selling?
Recent insider activity shows net buying of $121.05M.
Explore More
Continue the stock analysis
Jump to another research area for this company.